Eli Lilly & Co Stock Forecast for 2023 - 2025 - 2030

Updated on 06/04/2023

Stock Rating
14
Price Target
$400.00
Consensus
Outperform
Downside
-9.57%
Analysts
12
Stock Rating
14
Downside
-9.57%
Analysts
12
Price Target
$400.00

Eli Lilly & Co Stock Forecast and Price Target

Based on the current earnings figures, this year's price targets for Eli Lilly & Co were recently set by twelve distinguished experts, with an average mark of $400.00. If it reached this goal, it would represent a potential downside of approximately -9.57% from the previous closing price in June, 2023. The high end is $440.00, and the low is $202.00. If you're looking for information on Eli Lilly & Co stock, consider checking out the forecasts for comparable firms such as NYSE:BMY.

$400.00

-9.57% Downside

Outperform
Outperform

Eli Lilly & Co Fair Value Forecast for 2023 - 2025 - 2030

Eli Lilly & Co's Price has seen growth In the last three years, going from $142.85 to $163.89 – a gain of 14.74% In the next year, analysts believe that Fair Value will reach $228.70 – an increase of 39.54%. For the next eight years, the forecast is forFair Value to grow by 192.06%.

2023 Fair Value Forecast
$228.70
2024 Fair Value Forecast
$277.65
2025 Fair Value Forecast
$336.30
2026 Fair Value Forecast
$380.53
2027 Fair Value Forecast
$402.52
2028 Fair Value Forecast
$439.65
2029 Fair Value Forecast
$458.57
2030 Fair Value Forecast
$478.68
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$156.97 Buy/Sell $178.79 14.99%
PFE Stock Forecast Pfizer Inc Outperform 3
$38.36 Buy/Sell $47.96 37.25%
MRK Stock Forecast Merck Outperform 5
$112.52 Buy/Sell $99.57 4.87%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$65.66 Buy/Sell $80.99 26.41%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$739.95 Buy/Sell $796.73 5.68%

Eli Lilly & Co Revenue Forecast for 2023 - 2025 - 2030

Eli Lilly & Co's Revenue has seen growth In the last three years, going from $22.32B to $28.54B – a gain of 27.88% In the next year, analysts believe that Revenue will reach $30.45B – an increase of 6.70%. For the next eight years, the forecast is forRevenue to grow by 67.99%.

2023 Rev Forecast
$30.45B
2024 Rev Forecast
$34.27B
2025 Rev Forecast
$38.90B
2026 Rev Forecast
$42.26B
2027 Rev Forecast
$43.57B
2028 Rev Forecast
$45.83B
2029 Rev Forecast
$47.19B
2030 Rev Forecast
$47.95B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 13
$333.78 Buy/Sell $363.29 -2.33%
ZTS Stock Forecast Zoetis Outperform 18
$171.88 Buy/Sell $209.70 19.27%
BAX Stock Forecast Baxter International Inc Outperform 17
$41.33 Buy/Sell $60.73 40.33%

Eli Lilly & Co Dividend per Share Forecast for 2023 - 2025 - 2030

In the last three years, Dividend per Share for Eli Lilly & Co has grown by 75.19%, going from $2.58 to $4.52. According to 11 analysts, Eli Lilly & Co's Dividend per Share will fall by 7.08% in the next year, reaching $4.20. Over the next eight years, experts anticipate that Dividend per Share growth for Eli Lilly & Co will be 165.27%.

2023 DPS Forecast
$4.20
2024 DPS Forecast
$4.68
2025 DPS Forecast
$5.34
2026 DPS Forecast
$5.47
2027 DPS Forecast
$7.88
2028 DPS Forecast
$9.07
2029 DPS Forecast
$10.43
2030 DPS Forecast
$11.99
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$193.67 Buy/Sell $244.18 29.60%
VTRS Stock Forecast Viatris Outperform 8
$9.33 Buy/Sell $13.70 44.69%
UTHR Stock Forecast United Therapeutics Outperform 12
$217.22 Buy/Sell $280.69 35.81%

Eli Lilly & Co Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Eli Lilly & Co's Free Cash Flow has increased by 117377026.78%, going from $3.80B to $4463.50T. 10 analysts predict Eli Lilly & Co's Free Cash Flow will decrease by 100.00% in the next year, reaching $8.00B. By 2030, professionals predict that Eli Lilly & Co's Free Cash Flow will decrease by 100.00%, to $15.12B.

2023 FCF Forecast
$8.00B
2024 FCF Forecast
$9.32B
2025 FCF Forecast
$10.94B
2026 FCF Forecast
$12.77B
2027 FCF Forecast
$14.28B
2028 FCF Forecast
$14.82B
2029 FCF Forecast
$15.14B
2030 FCF Forecast
$15.12B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$37.72 Buy/Sell $83.92 93.53%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$41.75 Buy/Sell $52.42 19.76%
CYTK Stock Forecast Cytokinetics Outperform 10
$38.63 Buy/Sell $62.67 55.32%

Eli Lilly & Co Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Eli Lilly & Co's Net Income has decreased from $8.32B to $6.24B – a 24.93% drop. In the next year, analysts predict that Net Income will reach $8.82B – an increase of 41.22%. For the next eight years, the forecast is for Net Income to grow by 178.14%.

2023 NI Forecast
$8.82B
2024 NI Forecast
$10.57B
2025 NI Forecast
$12.76B
2026 NI Forecast
$13.95B
2027 NI Forecast
$15.07B
2028 NI Forecast
$16.01B
2029 NI Forecast
$16.68B
2030 NI Forecast
$17.37B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$132.82 Buy/Sell $163.67 23.48%
NEOG Stock Forecast Neogen Hold 16
$18.51 Buy/Sell $37.00 37.76%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$23.26 Buy/Sell $0.00 26.83%

Eli Lilly & Co EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Eli Lilly & Co's EBITDA has grown, increasing from $7.23B to $9.43B – an increase of 30.44%. For next year, the 13 analysts predict EBITDA of $11.82B, which would mean an increase of 25.25%. Over the next eight years, the pros' prediction is EBITDAof $20.45B, which would mean a eight-year growth forecast of 116.79%.

2023 EBITDA Forecast
$11.82B
2024 EBITDA Forecast
$14.01B
2025 EBITDA Forecast
$17.51B
2026 EBITDA Forecast
$16.01B
2027 EBITDA Forecast
$17.17B
2028 EBITDA Forecast
$17.93B
2029 EBITDA Forecast
$18.95B
2030 EBITDA Forecast
$20.45B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$26.56 Buy/Sell $73.38 -28.46%
INDV Stock Forecast Indivior PLC Buy 14
£165.80 Buy/Sell £3.79 -97.14%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$39.09 Buy/Sell $79.67 99.54%

Eli Lilly & Co EBIT Forecast for 2023 - 2025 - 2030

Eli Lilly & Co's EBIT has increased by 36.31% In the last two years, going from $6.00B to $8.18B. In the next year, analysts expect EBIT to reach $10.24B – an increase of 25.18%. For the next eight years, the forecast is for EBIT to grow by 143.31%.

2023 EBIT Forecast
$10.24B
2024 EBIT Forecast
$12.44B
2025 EBIT Forecast
$15.21B
2026 EBIT Forecast
$16.48B
2027 EBIT Forecast
$18.00B
2028 EBIT Forecast
$19.05B
2029 EBIT Forecast
$19.75B
2030 EBIT Forecast
$19.90B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$46.70 Buy/Sell $41.00 -5.78%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$11.03 Buy/Sell $12.60 13.33%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$33.53 Buy/Sell $35.50 1.40%

Eli Lilly & Co EPS Price Prediction Forecast for 2023 - 2025 - 2030

Eli Lilly & Co's EPS has seen growth In the last three years, going from $6.04 to $6.93 – a gain of 14.74% In the next year, analysts believe that EPS will reach $9.67 – an increase of 39.54%. For the next eight years, the forecast is forEPS to grow by 192.06%.

2023 EPS Forecast
$9.67
2024 EPS Forecast
$11.74
2025 EPS Forecast
$14.22
2026 EPS Forecast
$16.09
2027 EPS Forecast
$17.02
2028 EPS Forecast
$18.59
2029 EPS Forecast
$19.39
2030 EPS Forecast
$20.24
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$72.13 Buy/Sell $195.43 119.74%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$259.94 Buy/Sell $170.08 -32.68%
USNA Stock Forecast USANA Health Sciences Hold 14
$63.54 Buy/Sell $104.00 -10.29%